undefined
No data
FDA issued to pharmaceutical companies cGMP warning letter key content!
I believe that no pharmaceutical company will want to receive a Warning Letter from FDA. based on past FDA inspection experience and reading FDA warning letters over the years, colleagues of the Durst team have summed up the following key contents of the warning letter for the reference of pharmaceutical colleagues. from the key contents of the FDA warning letter, we can see the defects that are easy to occur in the FDA inspection process, which is convenient for pharmaceutical colleagues to avoid the same mistakes in their work.
Contact Information
Durst (Shenzhen) Consulting Service Co., Ltd.
Contact Phone:86-18826007039
E-mail:consulting@delsalt.com
Address: C19, Building 1, Yongheyuan, Zhuangbian Community, xixiang street, Bao 'an District, Shenzhen City, Guangdong Province
Sweep to identify concerns:
Scan attention consultation